Suited to general or non-prescribing neurologists, registrars looking to develop a specialism, pharmacists or established clinical nurse specialists (CNS), this course aims to provide a detailed overview of the modern management of MS across diagnosis and treatment. With in-depth learning around disease-modifying treatments (DMTs), including the safe use and monitoring of them, and areas for especial monitoring and care to avoid serious adverse events.
Promoting active and holistic management of MS throughout the applied-learning model and with inspiring speakers sharing their experiences and expertise, the course seeks to inspire attendees to implement change and optimise care for their own patients. With a large component of the course focussing on setting-up and running a comprehensive MS service and an intermodule project encouraging really practical research into attendees own local practice, the Intermediate MasterClass is both a learning experience and a catalyst for change.
To complete the course: Delegates must complete all aspects of module 1, the inter-module project, and module 2 to gain their certificate. Projects, which should epitomise learning in practice and focus on an unmet need locally, will be presented to their peers and faculty within module 2.
The course is fully funded across both modules including travel allowance for clinicians practising in the UK.
Upcoming Intermediate MasterClasses
► MS Intermediate MasterClass 11 – Module 2
How are the courses taught?
The courses are taught through a range of learner-centred methods including formal lectures, interactive workshops, and an intermodule project. Additional seminars and learning opportunities will be undertaken more locally with your mentor and through distance learning. Learners must complete an intermodule workplace service project during the six/eight month break before returning to Module 2 to present their findings.
A note from our Academic Director, Prof Gavin Giovannoni:
‘To cement the learning objectives from your first MasterClass module, its essential that you complete a project that builds on that learning.
Choose a project that addresses an unmet need in your local service, and find something that sparks your interest. Talk it through with your mentor – or come find me at module 1. We don’t want you to choose something ‘quick and easy’ or to present a proposal or case discussion. Without this project you cannot pass the course or receive your CPD certificate – but we don’t want you to look at it as a ‘tickbox’ to complete. We want to see you putting you’re learning into practice.
Our ambition is for your projects to be the catalyst for change in your practice – to see them improve outcomes for people with MS.’
Needing some project inspiration or wondering what past delegates have done? Take a look at our Snapshots or read about the work of some of our faculty members from the flagship Parkinson’s Academy established 16 years ago.
MS Intermediate MasterClass 11 will be awarded CPD accreditation from the Royal College of Physicians of the United Kingdom upon completion of Module 2. The 2019 MasterClass was approved for 30 category 1 (external) CPD credit(s). Full conditions of approval are listed in our guidelines. 12 External credits may be claimed for an MSc or equivalent activity.
What will it cost?
The MS MasterClasses are fully funded for delegates working in the UK, which includes accommodation on the nights during both modules and if required the night prior to each module. Your travel grant will be discussed once your application has been approved and is for UK delegates only.
We welcome international delegates on the MS MasterClasses, however there is a charge of £1000 (incl. VAT) for each place and you are responsible for your own travel arrangements. Your attendance fee will cover accommodation on the nights during both modules, all meals and course materials. International delegates may be able to obtain funding for the MasterClass from a pharmaceutical company – we suggest that you contact your local pharmaceutical representatives.
This activity has been supported by sponsorship from Roche Products Limited, Biogen Idec Limited and Sanofi Genzyme. The sponsors have had no control over the educational content of this activity.